Primary Objective:
To determine the safety and tolerability of the OnVagus device in patients wearing it while receiving chemotherapy.
Secondary Objective:
To determine the rate of cachexia arrest, as defined by weight stabilization or gain
Exploratory Objectives:
To analyze the changes in chemokine (C-C motif) ligand 2 (CCL2), tumor necrosis factor α (TNFa), acetylcholine (ACh), Growth/differentiation factor 15 (GDF15), Lipocalin-2 (LCN2), and liver function tests (LFTs) while patients receive vagal blockade.
To determine the device's impact on progression-free survival (PFS) and overall survival (OS) between patients receiving vagal blockade.
